BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a Healthcare company (Biotechnology) with a market capitalization of $11.3B. The Maz Rating grades it against the other companies in its sector.
BioMarin Pharmaceutical Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $58.51, BioMarin Pharmaceutical Inc. trades at 3.1x sales and 1.8x book value, with an EV/EBITDA of 33.2. Over the last twelve months it generated about $3.7B of revenue and a net loss of $18M. It runs a gross margin of 75.4%, an operating margin of 6.5% and a net margin of -0.5%. It shows return on equity of -0.3%, return on invested capital of -1.0% and a free cash flow yield of 4.9%. On the balance sheet: a debt-to-equity ratio of 0.67 and a current ratio of 2.44. Over the past 52 weeks the share price ranged from $49.26 to $70.98, with a beta of 0.21.
BioMarin Pharmaceutical Inc. does not currently pay a dividend.
41 Wall Street analyst ratings cover the stock: 29 Buy and 12 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, BioMarin Pharmaceutical Inc. (BMRN) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 35.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.31% / 30% · Interest income / Revenue 0.45% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 35.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.31% / 33% · Receivables / Mkt Cap (36m) 9.23% / 49% · Interest income / Revenue 0.45% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 35.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.31% / 33.33% · Receivables / Mkt Cap (24m) 9.23% / 33.33% · Interest income / Revenue 0.45% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 26.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 13.7% / 33.33% · Receivables / Avg Assets (4Q) 10.0% / 33.33% · Interest income / Revenue 0.45% / 5% | Pass |
| FTSE | Debt / Total Assets 36.1% / 33.33% · (Cash+ST Inv) / Total Assets 6.36% / 33.33% · (Cash+Recv) / Total Assets 15.7% / 33.33% · Interest income / Revenue 0.45% / 5% | Fail |
It depends on the standard you follow. As of September 2026, BioMarin Pharmaceutical Inc. (BMRN) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
No. BioMarin Pharmaceutical Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.45% of each dividend: BioMarin Pharmaceutical Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.